Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2006 2
2007 6
2008 7
2009 3
2010 6
2011 7
2012 3
2013 4
2014 3
2015 6
2016 4
2017 3
2018 4
2019 7
2020 2
2021 5
2022 4
2023 7
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

75 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab and first-line taxane chemotherapy in metastatic breast cancer patients with a HER2-negative tumor and HER2-positive circulating tumor cells: a phase II trial.
Verschoor N, Bos MK, de Kruijff IE, Van MN, Kraan J, Drooger JC, Zuetenhorst JM, Wilting SM, Sleijfer S, Jager A, Martens JWM. Verschoor N, et al. Among authors: kraan j. Breast Cancer Res Treat. 2024 May;205(1):87-95. doi: 10.1007/s10549-023-07231-4. Epub 2024 Jan 31. Breast Cancer Res Treat. 2024. PMID: 38291268 Free PMC article. Clinical Trial.
Tumor-agnostic ctDNA levels by mFAST-SeqS in first-line HR-positive, HER2 negative metastatic breast cancer patients as a biomarker for survival.
Verschoor N, de Weerd V, Van MN, Kraan J, Smid M, Heijns JB, Drooger JC, Zuetenhorst JM, van der Padt-Pruijsten A, Jager A, Sleijfer S, Martens JWM, Wilting SM. Verschoor N, et al. Among authors: kraan j. NPJ Breast Cancer. 2023 Jul 14;9(1):61. doi: 10.1038/s41523-023-00563-w. NPJ Breast Cancer. 2023. PMID: 37452019 Free PMC article.
mFast-SeqS-based aneuploidy score in circulating cell-free DNA is a prognostic biomarker in prostate cancer.
Isebia KT, Mostert B, Deger T, Kraan J, de Weerd V, Oomen-de Hoop E, Hamberg P, Haberkorn BCM, Helgason HH, de Wit R, Mathijssen RHJ, Lolkema MP, Wilting SM, van Riet J, Martens JWM. Isebia KT, et al. Among authors: kraan j. Mol Oncol. 2023 Sep;17(9):1898-1907. doi: 10.1002/1878-0261.13449. Epub 2023 Aug 18. Mol Oncol. 2023. PMID: 37178439 Free PMC article.
CABA-V7: a prospective biomarker selected trial of cabazitaxel treatment in AR-V7 positive prostate cancer patients.
Isebia KT, Mostert B, Belderbos BPS, Buck SAJ, Helmijr JCA, Kraan J, Beaufort CM, Van MN, Oomen-de Hoop E, Sieuwerts AM, van IJcken WFJ, van den Hout-van Vroonhoven MCGN, Brouwer RWW, Oole E, Hamberg P, Haberkorn BCM, Helgason HH, de Wit R, Sleijfer S, Mathijssen RHJ, Martens JWM, Jansen MPHM, van Riet J, Lolkema MP. Isebia KT, et al. Among authors: kraan j. Eur J Cancer. 2022 Dec;177:33-44. doi: 10.1016/j.ejca.2022.09.032. Epub 2022 Oct 6. Eur J Cancer. 2022. PMID: 36323051 Free article.
75 results